ARVN Q1 2023 Earnings — Arvinas, Inc. Revenue & Financial Results | Market Cap Arena

ARVNArvinas, Inc.

$907M

Q1 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$33M+22.6% YoY

Gross Profit

$31M94.8% margin

Operating Income

-$88M-269.8% margin

Net Income

-$82M-252.0% margin

EPS (Diluted)

$-1.52

QoQ Revenue Growth

-14.5%

Cash Flow

Operating Cash Flow

-$91M

Free Cash Flow

-$92M

Stock-Based Comp.

$20M

Balance Sheet

Total Assets

$1.2B

Total Liabilities

$665M

Stockholders' Equity

$511M

Cash & Equivalents

$130M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$33M	$27M	+22.6%
Gross Profit	$31M	$24M	+26.2%
Operating Income	-$88M	-$58M	-52.0%
Net Income	-$82M	-$63M	-29.2%